An update on cholangiocarcinoma associated with primary sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 26, Issue 3, 2010, Pages 236-245

  Fevery, Johan ^a   Verslype, Chris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Brush cytology; Cholangiocarcinoma; Inflammatory cytokines; Liver transplantation; MicroRNA; PET; PSC; Resection; Serum markers; Tissue markers

Indexed keywords

BETA CATENIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; CYCLINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMATOPORPHYRIN DERIVATIVE; MICRORNA; MUCIN; OXALIPLATIN; PROTEIN P53; SCLEROPROTEIN; URSODEOXYCHOLIC ACID; WNT PROTEIN;

ANEUPLOIDY; APOPTOSIS; BILE DUCT CARCINOMA; BILIARY TRACT ENDOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLANGITIS; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER RESECTION; LIVER TRANSPLANTATION; MUTAGENESIS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; REVIEW;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; HUMANS;

EID: 77951296669     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328337b311     Document Type: Review

References (70)

1. LaRusso NF, Wiesner RH, Ludwig J. Sclerosing cholangitis. In: Bircher et al., editors. Oxford textbook of clinical hepatology. 2nd ed. Oxford Medical Publications; 1999. pp. 1121-1130.
2. Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut 2001; 48:430-434. (Pubitemid 32269576)
3. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50:158-164.
4. Lewis JT, Talwalkar JA, Rosen CB, et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007; 31:907-913.
5. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48:308-321. (Pubitemid 351975555)
6. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151-156. (Pubitemid 34146420)
7. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48:1106-1117.
8. Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52:3123-3135. (Pubitemid 47512534)
9. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523-526. (Pubitemid 38524134)
10. Broomé U, Olsson R, Lööf L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610-615. (Pubitemid 26111384)
11. Sirica AE, Nathanson MH, Gores GJ, Larusso NF. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference. Hepatology 2008; 48:2040-2046.
12. Lewis JT, Talwalkar JA, Rosen CB, et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010; 34:27-34.
13. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation- fibrosis-cancer axis. Hepatology 2007; 46:590-597.
14. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130:2113-2129. (Pubitemid 43816961)
15. Sirica AE, Zhang Z, Lai GH, et al. A novel 'patient-like' model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 2008; 47:1178-1190. (Pubitemid 351547904)
16. Piscaglia AC, Shupe TD, Pani G, et al. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocytecolony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol 2009; 51:77-92.
17. Komori J, Marusawa H, Machimoto T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008; 47:888-896. (Pubitemid 351449680)
18. Mott JL, Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007; 46:906-911.
19. Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45:42-52. (Pubitemid 46144363)
20. Thompson MD, Monga SP. Wnt/b-catenin signalling in liver health and disease. Hepatology 2007; 45:1298-1305.
21. Ahrendt SA, Rashid A, Chow JT, et al. p53 overexpression and k-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000; 7:426-431.
22. Dufour JF, Huber O, Kozma SC, et al. Tumour suppressors in liver carcinogenesis. J Hepatol 2007; 47:860-867. (Pubitemid 350051125)
23. Rizzi PM, Ryder SD, Portmann B, et al. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996; 38:265-268. (Pubitemid 26048700)
24. Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009; 45: 33-47.
25. Sandhu DS, Shire AM, Roberts LR. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int 2008; 28:12-27.
26. Obama K, Ura K, Li M, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005; 41:1339-1348. (Pubitemid 40770287)
27. Wang C, Maass T, Krupp M, et al. A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. J Hepatol 2009; 50:1122-1131.
28. Itatsu K, Zen Y, Yamaguchi J, et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol 2008; 39:710-719.
29. Kahraman A, Bronk SF, Cazanave S, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res 2009; 39:805-813.
30. Isomoto H. Epigenetic alterations associated with cholangiocarcinoma. Oncol Rep 2009; 22:227-232.
31. Deng S, Calin GA, Croce CM, et al. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008; 7:2643-2646.
32. O'Hara SP, Mott JL, Splinter PL, et al. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 2009; 136:17-25.
33. Mott JL. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 2009; 50:630-637.
34. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47:1955-1963. (Pubitemid 351952843)
35. Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008; 27:378-386.
36. Chen L, Yan HX, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50:358-369.
37. Selaru FM, Olaru AV, Kan T, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49:1595-1601.
38. Li Q, Yan W, Cheng S, et al. Introduction of G1 phase arrest in human hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the downregulation of TIMP3 and upregulation of the CDK inhibitors p21. Mol Biol Rep 2006; 33:257-263. (Pubitemid 44760395)
39. Forsbring M, Vik ES, Dalhus B, et al. Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis 2009; 30:1147-1154.
40. Lempinen M, Isoniemi H, Mäkisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007; 47:677-683. (Pubitemid 47503427)
41. Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102:2164-2170.
42. Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008; 47:90-96. (Pubitemid 351171045)
43. Alvaro D. Serum and biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 2009; 25:279-284.
44. Albiin N, Smith IC, Arnelo U, et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol 2008; 49:855-862.
45. Zhao P, Lu Y, Zhong M, et al. Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Acta Oncol 2008; 47:1557-1563.
46. Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol 2009; 51:93-101.
47. Tan FL, Ooi A, Huang D, et al. p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer 2009. [Epub ahead of print]
48. Nishino R, Honda M, Yamashita T, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008; 49:207-216.
49. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009; 50:791-798.
50. Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010; 51:174-180.
51. Prytz H, Keiding S, Björnsson E, et al., Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006; 44:1572-1580. (Pubitemid 44953662)
52. Tischendorf JJ, Krüger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38:665-669. (Pubitemid 44044391)
53. Tischendorf JJ, Meier PN, Schneider A, et al. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2007; 42:1011-1017. (Pubitemid 47037125)
54. Tsai S, Pawlik TM. Primary sclerosing cholangitis: the role of extrahepatic biliary resection. Adv Surg 2009; 43:175-188.
55. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007; 19:487-491. (Pubitemid 46725755)
56. Becker NS, Rodriguez JA, Barshes NR, et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18- year period. J Gastrointest Surg 2008; 12:117-122.
57. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242:451-461.
58. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2:774-779. (Pubitemid 36342621)
59. Wu Y, Johlin FC, Rayhill SC, et al. Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl 2008; 14:279-286. (Pubitemid 351425479)
60. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10:186-189. (Pubitemid 352016246)
61. Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin Gastroenterol 2008; 24:384-388. (Pubitemid 351535899)
62. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82:1703-1707.
63. Wang JB, Liu LX, Pan SH, et al. Therapeutic effect of photodynamic therapy using hematoporphyrin monomethyl ether (HMME) on human cholangiocarcinoma cell line QBC939. Neoplasma 2010; 57:79-85.
64. Ortner MA. Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr Opin Gastroenterol 2009; 25:472-476.
65. Gao F, Bai Y, Ma SR, et al. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2009. [Epub ahead of print]
66. Zoepf T. Photodynamic therapy of cholangiocarcinoma. HPB (Oxford) 2008; 10:161-163. (Pubitemid 352016239)
67. Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 2008; 10:164-167. (Pubitemid 352016240)
68. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study: The UK ABC-01 Study. Br J Cancer 2009; 101:621-627.
69. Valle JW, Wasan HS, Palmer DD, et al. Gemcitabine with or without cisplatin in patients (patients) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 2009; 27:15s. (suppl; abstr 4503).
70. Poggi G, Amatu A, Montagna B, et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009; 32:1187-1192.